KURA News and Press, Kura Oncology Inc. From 07/23/23

2023-07-23 10:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-07-13 08:30:00 ET Summary June 2023 saw significant insider purchases in Lucid Group, Diversified Healthcare Trust, Akoya Biosciences, and Axon Enterprise. The Public Investment Fund bought $1.8 billion worth of shares in Lucid Group, increasing its ownership to 74.95%. Diver...

2023-07-12 16:23:16 ET Summary Kura Oncology, Inc. has additional updated results released from the KOMET-001 study, as part of an oral late-breaker presentation shown on June 11, 2023 at the EHA; 35% achieved CR with full count recovery. The global Acute Myeloid Leukemia market i...

2023-06-14 07:29:15 ET Kura Oncology ( NASDAQ: KURA ) prices public offering of 5.66M common stock at a price to the public of $11.50 per share and 3.03M pre-funded warrants at $11.4999 per pre-funded warrant, with the exercise price of the pre-funded warrants is $0.0001...

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of common stock and pre...

2023-06-13 16:12:59 ET Kura Oncology ( NASDAQ: KURA ) plans to issue and sell $100 million worth of common stock or pre-funded warrants to purchase its common stock in a public offering, the company said Tuesday. Underwriters of the offering have a 30-day option to purch...

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to mark...

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib – – Ziftomenib monot...

– Late-breaking abstracts scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023 – – Data from Phase 1 trial of ziftomenib to be presented at the late-breaking oral session on Sunday, June 11, 2023 – – Management to host vi...

2023-05-25 16:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...